Nateglinide for type 2 diabetes

被引：0
|
作者：
不详
机构：
来源：
MEDICAL LETTER ON DRUGS AND THERAPEUTICS | 2001年 / 43卷 / 1101期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
下载
收藏
页码：29 / 30
页数：2
相关论文
共 50 条
  • [31] Effect of nateglinide on the postprandial triglyceride and lipoprotein concentrations in subjects at risk for type 2 diabetes
    Johanson, E
    Axelsen, M
    Jansson, PA
    Taskinen, MR
    Smith, U
    DIABETES, 2003, 52 : A211 - A211
  • [32] Nateglinide reduces post-prandial glucose and methylglyoxal levels in type 2 diabetes
    Beisswenger, PJ
    Tamber, M
    Lapoint, N
    Keshavarz, T
    Howell, S
    Baron, M
    DIABETES, 2004, 53 : A471 - A471
  • [33] Development of pharmacogenomic algorithm to optimize nateglinide dose for the treatment of type 2 diabetes mellitus
    Naushad, Shaik Mohammad
    Hussain, Tajamul
    Alrokayan, Salman A.
    Kutala, Vijay Kumar
    PHARMACOLOGICAL REPORTS, 2022, 74 (05) : 1083 - 1091
  • [34] Multiple effects of Nateglinide on glucose metabolism in obese patients with type 2 diabetes mellitus
    Nishimura, H
    Shintani, M
    Maeda, K
    Okuda, J
    Tanaka, S
    DIABETES, 2002, 51 : A609 - A609
  • [35] Nateglinide improves glycemic control alone and in combination with trofilitazone in patients with type 2 diabetes
    Rosenstock, J
    Gatlin, M
    Mallows, S
    Bush, C
    DIABETES, 2000, 49 : A123 - A123
  • [36] Study of nateglinide in Japan: Long-term treatment of patients with type 2 diabetes
    Hiroto Taki
    Toshio Maki
    Takako Iso
    Kenji Iwamoto
    Taiichi Kajiura
    Advances in Therapy, 2006, 23 : 307 - 324
  • [37] Study of nateglinide in Japan: Long-term treatment of patients with type 2 diabetes
    Taki, H
    Maki, T
    Iso, T
    Iwamoto, K
    Kajiura, T
    ADVANCES IN THERAPY, 2006, 23 (02) : 307 - 324
  • [38] Development of pharmacogenomic algorithm to optimize nateglinide dose for the treatment of type 2 diabetes mellitus
    Shaik Mohammad Naushad
    Tajamul Hussain
    Salman A. Alrokayan
    Vijay Kumar Kutala
    Pharmacological Reports, 2022, 74 : 1083 - 1091
  • [39] Nateglinide - A new member of the meglitinide family for postprandial glucose control in type 2 diabetes
    Schrand, LM
    Spanheimer, RG
    FORMULARY, 2000, 35 (10) : 798 - +
  • [40] Comparison of the effects of nateglinide and glibenclamide on postprandial glucose and lipid fluxes in Type 2 diabetes
    Dimitriadis, G
    Boutati, E
    Lambadiari, V
    Mitrou, P
    Maratou, E
    Houssianakou, E
    Raptis, S
    DIABETOLOGIA, 2002, 45 : A245 - A245
12345